Gilead Sciences Inc. (NASDAQ:GILD)’s anti-AIDS pill Truvada has been approved as a preventative medicine for the virus that causes AIDS. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 2.79%. On last trading day company shares ended up $80.97. Analysts mean target price for the company is $99.50. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 8.12%.
United Community Financial (NASDAQ:UCFC) Director Zahid Afzal purchased 31,893 shares of the company’s stock on the open market in a transaction dated Tuesday, May 6th. The shares were purchased at an average price of $3.35 per share, with a total value of $106,841.55. Following the completion of the acquisition, the director now directly owns 39,046 shares in the company, valued at approximately $130,804. United Community Financial Corp (NASDAQ:UCFC) shares fell -4.20% in last trading session and ended the day on $3.19. UCFC return on assets is 0.30%.United Community Financial Corp (NASDAQ:UCFC) quarterly performance is -6.45%.
bluebird bio, Inc. (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, reported financial results and operational highlights for the quarter ended March 31, 2014. Revenue was $6.3 million during the three months ended March 31, 2014, compared to $1.1 million for the three months ended March 31, 2013. bluebird bio Inc. (NASDAQ:BLUE) shares moved up 27.34% in last trading session and was closed at $24.73, while trading in range of $19.69 – $25.09. bluebird bio Inc. (NASDAQ:BLUE) year to date (YTD) performance is 17.87%.
Criteo SA (ADR) (NASDAQ:CRTO) Revenue in the first quarter 2014 increased 60.8% (or 68.4% at constant currencies1) to EURO152.5 million, compared with EURO94.9 million in the first quarter 2013. Criteo SA (ADR) (NASDAQ:CRTO) ended the last trading day at $33.50. Company weekly volatility is calculated as 12.12% and price to cash ratio as 32.13.Criteo SA (ADR) (NASDAQ:CRTO) showed a positive weekly performance of 22.89%.